Business Context and Reporting Period
This Form 8-K is filed by eXegenics Inc. (not OPKO Health, Inc.) for the reporting period ending April 9, 2007. The registrant is incorporated in Delaware with principal executive offices in Miami, Florida. The filing discloses material corporate governance changes regarding accounting oversight and executive leadership.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on non-financial operational changes and executive compensation terms.
Material Changes
- Change in Certifying Accountant: The Board of Directors approved the dismissal of Rotenberg & Co., LLP and the engagement of Ernst & Young LLP as the independent registered public accounting firm.
- Audit History: Reports by Rotenberg for fiscal years 2005 and 2006 contained no adverse opinions, disclaimers, or qualifications. No disagreements regarding accounting principles or audit scope occurred during the tenure of Rotenberg.
- Executive Appointment: Dale Pfost, PhD was appointed as President of the Company effective April 9, 2007.
Guidance, Outlook, and Management Commentary
The filing contains no forward-looking guidance, market outlook, or discussion of risks and contingencies. Management commentary is limited to the terms of the new employment agreement for the President:
- Compensation: Annual base salary of $325,000, subject to Board discretion for increases.
- Bonus: A one-time bonus of $40,000 for fiscal year 2006, payable by April 19, 2007. Future bonuses are discretionary based on performance.
- Equity: Grant of an option to purchase 300,000 shares of common stock, contingent on shareholder approval of a new equity incentive plan. The option vests over 48 months.
- Termination: The agreement includes a 12-month severance provision if employment is terminated without cause or for good reason.
Investor Verification Checklist
- Verify the shareholder approval status of the new equity incentive plan required for Dr. Pfost's stock option grant.
- Review the letter from Rotenberg & Co., LLP (Exhibit 16.1) to confirm their concurrence with the Company's statements regarding the dismissal.
- Confirm the effective date of Ernst & Young LLP's engagement and the scope of their initial audit responsibilities.
- Check subsequent filings for the actual grant date and exercise price of the 300,000 stock options.